PsyBio Therapeutics Correlations
| PSYBF Stock | USD 0.0001 0.00 0.00% |
The current 90-days correlation between PsyBio Therapeutics Corp and Rigel Pharmaceuticals is -0.06 (i.e., Good diversification). The correlation of PsyBio Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
PsyBio Therapeutics Correlation With Market
Significant diversification
The correlation between PsyBio Therapeutics Corp and DJI is 0.05 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding PsyBio Therapeutics Corp and DJI in the same portfolio, assuming nothing else is changed.
PsyBio |
The ability to find closely correlated positions to PsyBio Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PsyBio Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PsyBio Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PsyBio Therapeutics Corp to buy it.
Related Correlations Analysis
| -0.59 | 0.78 | -0.43 | 0.05 | RIGL | ||
| -0.59 | -0.66 | 0.61 | 0.25 | GERN | ||
| 0.78 | -0.66 | -0.7 | -0.09 | VSTM | ||
| -0.43 | 0.61 | -0.7 | 0.46 | IMMP | ||
| 0.05 | 0.25 | -0.09 | 0.46 | ELEV | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between PsyBio Pink Sheet performing well and PsyBio Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze PsyBio Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RIGL | 3.41 | 1.06 | 0.37 | 0.63 | 2.40 | 9.10 | 55.18 | |||
| GERN | 2.21 | (0.24) | 0.00 | (0.10) | 0.00 | 4.17 | 14.00 | |||
| VSTM | 4.31 | 1.25 | 0.23 | 1.41 | 4.51 | 12.84 | 31.27 | |||
| IMMP | 2.39 | (0.35) | 0.00 | (0.43) | 0.00 | 4.89 | 18.55 | |||
| ELEV | 3.46 | (0.37) | 0.00 | (0.05) | 0.00 | 5.77 | 22.21 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in PsyBio Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Rebalancing Now
Portfolio RebalancingAnalyze risk-adjusted returns against different time horizons to find asset-allocation targets |
| All Next | Launch Module |
PsyBio Therapeutics Corporate Management
| Andrew Jones | Inventor Board | Profile | |
| Ross Carmel | Chief Director | Profile | |
| Noah Davis | S CFO | Profile | |
| Evan Levine | CEO CoFounder | Profile | |
| MBA MBE | Chief Officer | Profile |